Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06208124 · ClinicalTrials.gov registry record · Phase 1
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
A Phase 1 study, sponsored by Immuneering Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06208124 is a Phase 1 study that has completed, run by Immuneering Corporation. The registered enrollment target is 30 participants.
The verdict
NCT06208124, a Phase 1 study, has completed, sponsored by Immuneering Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
Interventions
- DRUG IMM-6-415
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06208124
The ClinicalTrials.gov registry entry for NCT06208124 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immuneering Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMM-6-415 is the first listed.
NCT06208124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06208124 about?
NCT06208124 is a clinical study titled "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors". This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations.
What is the current status of trial NCT06208124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-02-27. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06208124?
The interventions under investigation include: IMM-6-415 (DRUG).
Who is sponsoring clinical trial NCT06208124?
This trial is sponsored by Immuneering Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.